Skip to main content
. 2022 Feb 17;15(2):241. doi: 10.3390/ph15020241

Figure 1.

Figure 1

AG1024 exerted anti-coronaviral activity against TGEV and HCoV-OC43. (A) AG1024 inhibited TGEV coronaviral activity in a dose-dependent manner. IFA was performed to examine the dose responses of AG1024 on the viral inhibition in TGEV infected ST cells (A(a,b)). Western analysis with an antibody against TGEV N protein was also performed for an additional anti-viral inhibition measurement for AG1024 against TGEV (A(c)). Cell viability was determined by the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit (MTS) after 6 h. (B) AG1024 inhibited HCoV-OC43 coronaviral activity in a dose-dependent manner. IFA were performed to examine the dose responses of AG1024 on the viral inhibition in HCoV-OC43 (0.1 MOI) infected HCT-8 cells after 24 h treatment (B(a,b)). Western analysis with antibody against HCoV-OC43 N protein was also performed for an additional viral inhibition measurement for AG1024 against HCoV-OC43 (0.1 MOI) in HCT-8 cells (B(c)). Hoechst dye was applied to counter-stain the nuclei (blue) and used to determine relative cell viability, which was used to normalize anti-viral activity. **, p < 0.01. Data shown are averages ± S.D. of three independent experiments.